LANGHORNE, Pa., March 12, 2026
NEXGEL, Inc. has announced the consideration terms of an agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity Inc., a move expected to significantly expand the company’s presence in the rapidly growing regenerative medicine and biomaterials market. The agreement includes an upfront payment of $15 million and potential milestone payments of up to $20 million tied to future net sales targets, marking what company leadership describes as a transformational milestone in NEXGEL’s growth strategy. The acquisition will bring six established regenerative biomaterial products focused on tendon repair, skin grafts, and bone growth, all of which have already demonstrated clinical utility and established reimbursement pathways. The company expects the transaction to approximately triple its annual revenue to about $35 million and make NEXGEL immediately profitable once the deal closes, positioning the company for accelerated expansion in the medical technology sector.
Strategic Acquisition Strengthens Regenerative Medicine Portfolio
The proposed transaction represents NEXGEL’s most significant strategic expansion to date, providing access to a diversified portfolio of regenerative biomaterial technologies that have been used in clinical settings for more than a decade. These biomaterials are designed to support tissue repair and regeneration in medical procedures involving tendons, skin, and bone, making them valuable tools for surgeons treating complex injuries and chronic conditions.
According to the company, the portfolio includes products that are already commercialized and supported by insurance reimbursement frameworks, which may accelerate market adoption and revenue growth. In addition to the products themselves, the transaction is expected to transfer an experienced scientific and commercial team from Celularity, strengthening NEXGEL’s operational capabilities in research, product development, and commercialization. Company leadership believes that the combination of established regenerative technologies and an expanded expert team will allow NEXGEL to rapidly scale its presence in the regenerative medicine and biomaterials industry while delivering innovative medical solutions to healthcare providers.
Hydrogel Technology and Biomaterials Innovation
NEXGEL has built its reputation as a leading developer of high-water-content hydrogel technologies, which are widely used in healthcare, consumer products, and over-the-counter medical applications. The company has more than two decades of experience developing electron-beam cross-linked hydrogel materials, which are designed to provide biocompatibility, flexibility, and moisture retention properties ideal for wound care, medical patches, and tissue regeneration applications. Through this acquisition, the company will expand beyond hydrogel manufacturing into regenerative biomaterial solutions that actively support tissue repair and healing, enabling physicians to treat conditions requiring structural and biological tissue support.
The newly acquired portfolio includes regenerative biomaterials used for tendon reconstruction, skin graft support, and bone growth stimulation, areas that are experiencing strong demand as healthcare systems increasingly adopt regenerative medicine approaches to improve patient recovery outcomes. By combining its advanced hydrogel platform with regenerative biomaterial technologies, NEXGEL aims to create a broader portfolio of medical solutions that address both acute injuries and long-term tissue repair challenges.
Financial Impact and Market Expansion
From a financial perspective, the agreement could significantly reshape NEXGEL’s business trajectory. The company projects that the transaction will increase its revenue base to approximately $35 million annually, effectively tripling its current revenue levels.
Additionally, the company anticipates becoming immediately profitable upon closing of the transaction, highlighting the strong commercial potential of the acquired product portfolio. The regenerative biomaterials market continues to expand rapidly as hospitals and surgeons seek advanced materials that promote faster healing and improved surgical outcomes. By acquiring an established portfolio of regenerative products with proven clinical use, NEXGEL positions itself to capitalize on the growing demand for biomaterials used in orthopedic, wound care, and reconstructive procedures.
Company executives also emphasized that the transaction aligns with NEXGEL’s long-term strategy to build shareholder value by expanding its capabilities in innovative healthcare technologies and advanced medical materials. As regenerative medicine continues to evolve, strategic acquisitions like this are expected to play a crucial role in shaping the future of medical device and biomaterials innovation worldwide.
Source: NEXGEL press release
